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ABSTRACT
In lymphoid organs, nurse-like cells (NLCs) show properties of tumor-associated 
macrophages, playing a crucial role in chronic lymphocytic leukemia (CLL) cell survival. 
Ibrutinib, a potent inhibitor of Bruton’s tyrosine kinase (BTK), is able to counteract 
pro-survival signals in CLL cells. Since the effects on CLL cells have been studied in 
the last years, less is known about the influence of ibrutinib on NLCs properties. We 
sought to determine how ibrutinib modifies NLCs functions focusing on the balance 
between immunosuppressive and inflammatory features. Our data show that ibrutinib 
targets BTK expressed by NLCs modifying their phenotype and function. Treatment 
with ibrutinib reduces the phagocytic ability and increases the immunosuppressive 
profile of NLCs exacerbating the expression of M2 markers. Accordingly, ibrutinib 
hampers LPS-mediated signaling, decreasing STAT1 phosphorylation, while allows 
IL-4-mediated STAT6 phosphorylation. In addition, NLCs treated with ibrutinib 
are able to protect CLL cells from drug-induced apoptosis partially through the 
secretion of IL-10. Results from patient samples obtained prior and after 1 month 
of treatment with ibrutinib show an accentuation of CD206, CD11b and Tie2 in the 
monocytic population in the peripheral blood. Our study provides new insights into the 
immunomodulatory action of ibrutinib on monocyte/macrophage population in CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the 
most common hematologic malignancy in the Western 
Countries. Despite several and important recent 
therapeutic advances, CLL is still an incurable disease. 
CLL is characterized by several clinical complications 
related to alterations in the immune system, including 
hypogammaglobulinemia, predisposition to infections 
and increased incidence of autoimmune disorders [1]. 
In this scenario, CLL cells are not innocent bystanders, 
but escape immunosurveillance and actively model the 
surrounding microenvironment to aberrantly orchestrate 
the function of immune effector cells [2]. In lymphatic 
tissues, CLL cells form areas of larger proliferating cells, 
known as pseudofollicles, establishing intimate contact 
with accessory cells [3].
Nurse-like cells (NLCs) are round or fibroblast-
shaped adherent cells differentiated from peripheral blood-
derived monocytes in vitro by high-mobility group protein 
B-1 (HMGB1) release from CLL cells and also detected 
in lymph nodes (LN) of CLL patients [4]. NLCs assume 
a pivotal role in leukemic clone maintenance supporting 
CLL survival, proliferation and protecting CLL from 
drug-induced apoptosis [5]. Accordingly, macrophage 
depletion was recently demonstrated as a promising 
strategy to sensitize CLL cells to apoptosis and inhibit 
disease progression in mouse model [6, 7]. Phenotypically, 
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NLCs are considered as CLL-specific M2-skewed tumor 
associated macrophages characterized by high CD11b, 
CD163, CD206, HLA-DR, HGF and IDO expression 
[8-12] and by dysregulation of genes involved in 
immunocompetence [13]. Likewise, NLCs were reported 
to promote T regulatory cell expansion and to sustain T 
cell immune dysfunctions in CLL [6, 12].
Ibrutinib is a potent irreversible inhibitor of Bruton’s 
tyrosin kinase (BTK) that has demonstrated exceptional 
safety and efficacy as a monotherapy in CLL patients 
[14, 15]. While durable clinical responses to single-agent 
ibrutinib are common in CLL, few patients experience 
a complete response. As consequence, in an effort to 
improve the already impressive effects of ibrutinib, it is 
currently investigated in combination with chemotherapy 
and monoclonal antibodies to facilitate the clearing of CLL 
cells and achieve deeper responses [16, 17]. Ibrutinib has 
been demonstrated to disrupt B-cell receptor (BCR) and 
NF-ĸB signaling pathways [18, 19], affecting lymphocytes 
migration and adhesion and counteracting the pro-survival 
signals derived from the microenvironment [20, 21]. 
However, ibrutinib is also a potent and clinically relevant 
immunomodulatory drug. Ibrutinib irreversibly binds IL-2 
inducible T cell kinase (ITK) leading to impairment of NK 
function with decreased ADCC [22] and to inhibition of 
Th2 cells activation upon TCR stimulation [23]. In treated 
patients, ibrutinib was associated with a normalization 
of CD3+CD4+ and CD3+CD8+ T cell count and Th17 
cell count, a decrease in T cell activation, proliferation 
and “pseudo-exhaustion” and a reduction of several 
inflammatory cytokines [23]. Overall, ibrutinib seems 
to correct the CLL-mediated chronic and dysfunctional 
activation of T cells, thereby enhancing immunotherapeutic 
strategies such as CAR-T cell therapy [24]. BTK is also 
expressed by macrophages and is required for phagocytosis 
and for macrophage lineage commitment to inflammatory 
profile [25]. Ibrutinib was reported to counteract the 
phagocytosis of rituximab-coated CLL cells by macrophages 
[26]. In ibrutinib-treated patients, NLCs can be generated 
in vitro and maintain their ability to rescue CLL cells 
from apoptosis [27]. Conversely, ibrutinib was found to 
disaggregate the interactions of macrophages and CLL cells 
in bone marrow microenvironment in treated patients [28].
These evidences prompted us to investigate the 
biological effects and mechanism mediated by ibrutinib on 
NLCs in CLL. Specifically, we sought to determine how 
ibrutinib modifies NLCs functions, focusing on the phagocytic 
activity and the balance between immunosuppressive and 
inflammatory features, and what are the consequences of 
these effects in the CLL-NLCs crosstalk. We demonstrate 
that treatment with ibrutinib targets BTK in NLCs, impairs 
phagocytosis and improves immunosuppressive phenotype. 
Overall, our study provides new insights into the effect of 
ibrutinib treatment on the modulation of immune elements in 
CLL tissue microenvironment, highlighting new mechanisms 
that may impair CLL sensitivity to ibrutinib.
RESULTS
BTK protein is expressed and targeted in NLCs 
by ibrutinib
Since the expression of BTK is not restricted to B 
cells, but it is also present in myeloid cells like monocytes/
macrophages [29], we sought to determine the expression 
profile and the activation status of BTK in NLCs. CLL cells 
were completely removed with several washes and after 
1 hour of incubation with ibrutinib NLCs were collected. 
The purity of NLCs preparations was assessed by phase-
contrast microscopy and by western blot with CD19 
antibody as shown in Supplementary Figure S1. As shown 
in Figure 1, NLCs revealed the expression of BTK with 
two different sites of phosphorylation (Tyr551 and Tyr223). 
We asked ourselves whether ibrutinib would interfere with 
BTK activation in these cells. NLCs were treated with 
ibrutinib 1 µM for 1 hour and BTK phosphorylation was 
determined. Ibrutinib reduced the level of phosphorylated 
BTK at both sites Tyr551 and Tyr223 as determined by 
western blot (Figure 1A and Figure 1B n=5). This result 
was also confirmed by flow cytometry (Figure 1C) and 
immunofluorescence microscopy (Figure 1D). Moreover, 
treatment with ibrutinib affected the activation of BTK-
downstream signaling pathways in NLCs as the PI3K and 
MAPK pathways leading to decreased AKT and ERK1/2 
phosphorylation (Supplementary Figure S1). These results 
imply that ibrutinib, targeting BTK in NLCs, may modify 
the biological functions of NLCs. As consequence, in 
the following experiments we explore the effects of 
BTK inhibition on pivotal mechanisms of macrophage 
functionality such as phagocytic capacity and M1 vs. M2 
polarization.
Ibrutinib affects phagocytic activity of NLCs
We first observed that after ibrutinib treatment the 
activation status and viability of NLCs was not affected 
(Figure 2A) and the morphology of NLCs was preserved 
(Supplementary Figure S2). In macrophages, BTK is 
involved in cytoskeleton remodeling and is required 
for optimal phagocytosis in the process of ingestion 
and phagosomes formation [30]. In line with these 
evidences, we investigated the ability of NLCs to engulf 
and ingest particles after treatment with ibrutinib. We 
treated NLCs with ibrutinib for 30 minutes or 1 hour 
and uptake of FITC-dextran particles was quantified 
by confocal microscopy. Ibrutinib decreased NLCs 
phagocytic activity compared to control (n=6, P<0.01 
for both time-points, Figure 2B). One of the main events 
accompanying phagocytic cup formation is the activation 
of MAC-1 (CD11b/CD18) [31]. Consistently, we also 
found an impairment of MAC-1 (CD11b/CD18) mean 
expression from 19% (±1%) to 13% (±1%) (n=6, P<0.05, 
Figure 2C).
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Ibrutinib enhances the immunosuppressive 
features of NLCs
BTK is involved in macrophages lineage commitment 
to inflammatory profile [25]. Several evidences have shown 
that NLCs are closely associated to tumor-associated 
macrophages (TAM) with peculiar M2-skewed properties 
[8, 10, 11]. We sought to determine whether treatment with 
ibrutinib further stimulates the expression of M2 polarization 
markers. After 24 hours of treatment, the transcriptional 
signature of NLCs exposed to ibrutinib showed the 
induction of M2 markers CD163 (P<0.01), IL10 (P<0.05), 
MRC1 (CD206) (P<0.01), CCL18 (P<0.01) and PD-L1 
(P<0.05) compared to control (n=8) and the concomitant 
down-regulation of M1 macrophages markers IL-1, TNFα 
and IL-2 (P<0.01 for all) (Figure 3A). These data were 
confirmed by an induction of the surface expression levels 
of M2 polarization markers CD163 and CD206 compared 
to untreated controls (n=7, P<0.01 for all) (Figure 3B and 
3C). Of interest, we also detected the induction of NAMPT, 
known to enhance the immunosuppressive profile of NLCs 
[11] (Figure 3A and 3D).
Ibrutinib stimulates M2 signaling pathways 
hampering a M1 profile in NLCs
M1 polarization is driven by IFNs and TLR 
signaling via STAT1, whereas M2 polarization is driven 
by IL-4 and IL-3 via STAT6 [32]. NLCs, treated for 1 
hour with ibrutinib, displayed an impairment of STAT1 
Figure 1: Ibrutinib specifically targets BTK in NLCs. NLCs (n=5) were treated or not with ibrutinib 1µM for 1h. Then, cell 
lysates were analyzed by immunoblotting using anti-phosphoBTK Tyr551, Tyr223, total BTK and anti-actin antibodies. Three representative 
samples are depicted in panel A. In panel B bar diagram represents densitometric quantification of bands relative to phospho-BTK Tyr551 
and phospho-BTK Tyr223 normalized on β-actin. Data are presented as mean ± SEM of 5 different NLCs samples (**P<0.01). NLCs were 
treated with ibrutinib for 1h before assessing expression of phospho-BTK Tyr551 and Tyr223 by flow cytometry C. and immunofluorescence 
microscopy D. (n=5, *P<0.05).
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phosphorylation that was hampered also after LPS 
stimulation for 3 hours compared to the corresponding 
controls (Figure 4A and Supplementary Figure S3A). 
Additionally, ibrutinib affected the levels of other 
signaling pathways crucial for M1 commitment such as 
phosphorylation of ERK, AKT and IĸB either in presence 
or absence of LPS stimulation (Figure 4B). Consistent 
with an impairment of M1 signaling pathways, we also 
observed in ibrutinib-treated NLCs an induction of 
STAT6 phosphorylation, that was also preserved upon 
IL4 stimulation (Figure 4C and Supplementary Figure 
S3B). In addition, treatment with ibrutinib enhanced 
the expression of the anti-inflammatory protein SHIP1 
(Figure 4D). These results indicate that inhibition of BTK 
in NLCs induced by ibrutinib intensifies the expression of 
M2-promoting properties counteracting the polarization 
toward M1 phenotype.
IL-10 secreted by ibrutinib-treated NLCs exerts 
protective effects on CLL cells
Inside tissue microenvironments, NLCs establish 
a bidirectional cross-talk with CLL cells, allowing their 
protection from spontaneous and drug-induced apoptosis 
[5, 33]. We exposed both CLL cells and NLCs to ibrutinib. 
In presence of ibrutinib, CLL cells cultured without NLCs 
were more sensitive to apoptosis if compared to CLL 
cells cultured with NLCs. Indeed, as recently reported 
also by others [27], we found that ibrutinib does not 
decisively hamper the protective effect mediated by 
NLCs on leukemic cells when both CLL cells and NLCs 
were exposed to ibrutinib 1 µM (Figure 5A). This result 
means that NLCs maintain the ability to nurture CLL 
cells also in presence of ibrutinib, mediating signals that 
partially rescue CLL cells from drug-induced apoptosis. 
Figure 2: Ibrutinib impairs the phaghocytic activity of NLCs. A. Bar diagram represents the formazan release by metabolically 
active NLCs treated with ibrutinib 1 µM for 24 hours compared to untreated control (n=6, ns). In the bottom panels, representative phase-
contrast micrographs demonstrate NLCs activation (as insoluble formazan precipitate) after treatment with ibrutinib. B. Box-plots summarize 
FITC-Dextran uptake by NLCs treated or not with ibrutinib 1 µM relative to 6 independent experiments (**P<0.01). In the bottom panels, 
two representative NLCs samples show confocal staining of NLCs with FITC-dextran, phalloidin and DAPI. C. Bar diagram shows the 
percentage of positive CD14+ NLCs stained for MAC-1 Ab or isotype control (n=6, P<0.05). Contour plots show a representative sample.
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Given the importance of soluble factors on protecting 
CLL cells from apoptosis in the microenvironment, we 
next sought to investigate one of the possible cytokines 
secreted by ibrutinib-treated NLCs that may be involved 
in the maintenance of CLL cell survival. Because ibrutinib 
further stimulated the gene expression level of IL-10 in 
NLCs (Figure 3A), we explored its role in the cross-talk 
between NLCs and CLL cells. First, we demonstrated that 
ibrutinib was able to improve NLCs secretion of IL-10 
(n=6, P<0.05) (Figure 5B). To better clarify the role of 
IL-10 in mediating CLL survival, we then cultured CD19+ 
CLL cells stimulated with IL-10 in a dose escalation 
experiment (from 0.1 ng/ml to 100 ng/ml) and we found 
a moderate protection from apoptosis at different doses 
(n=4, Supplementary Figure S4). We then analyzed the 
ability of ibrutinib to abrogate the pro-survival signal 
induced by IL-10 stimulation (1 ng/ml) in CLL cells 
after 24-48 hours of culture. As shown in Figure 5C, 
ibrutinib did not completely antagonize the ability of 
IL-10 to protect CLL cells from apoptosis (n=7) and to 
mediate signaling pathways through pSTAT3 and pERK 
(Figure 5D). Altogether these findings demonstrate an 
ibrutinib-mediated reinforcement of IL-10 production by 
NLCs and the inability of ibrutinib to totally counteract 
IL-10 signaling on CLL cells, suggesting that IL-10 may 
be involved in the mechanism of ibrutinib-resistance 
mediated by NLCs.
Ibrutinib alters the monocytic population in 
treated CLL patients
To understand the in vivo alterations mediated by 
ibrutinib, we analyzed the circulating CD14+ population 
in peripheral blood samples of CLL patients before and 
after one month of treatment with ibrutinib. The blood 
monocytic population, selected with anti-CD14, displayed 
a higher positivity for CD206 after treatment with ibrutinib 
in all 5 CLL patients with an increase of MFI from 37 (±4) 
to 49 (±45) (Figure 6A, upper panel, *P<0.05). Again, we 
detected an induction of CD11b in the CD14+ monocytic 
Figure 3: Exposure of NLCs to ibrutinib intensifies the expression of genes involved in M2 polarization. A. NLCs from 8 
CLL patients were exposed to ibrutinib or vehicle (DMSO) for 24 hours. Transcriptional levels of CD163, IL-10, MRC1, NAMPT, CCL18 
and PD-L1 (M2 polarization) and IL-1, TNFα, IL-2 (M1 polarization) were measured by quantitative reverse-transcription PCR (n=8, 
*P<0.05, **P<0.01). B. Diagrams show CD163 fluorescence intensity of NLCs treated with ibrutinib for 24 hours. Values of untreated 
and treated samples (n=7) are connected by lines (P<0.01). C. Bar diagram shows cumulative analysis of CD206 pixel intensity scoring at 
least 10 different cells for 3 different samples (P<0.01). On the right one representative sample stained for CD206, DAPI and phalloidin. 
D. NAMPT expression on NLCs, treated with ibrutinib 1 µM for the indicated time, was evaluated by confocal microscopy (n=6) using 
anti-NAMPT and secondary Alexa-488-anti-rabbit antibodies. Phalloidin and DAPI were used to counterstain. Graph shows cumulative 
data of green fluorescence pixel intensity (n=6, P<0.05).
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population by ibrutinib from 576 (±55) to 705 (±473) 
(Figure 6A, lower panel, *P<0.05). Next, we evaluated 
the extent of a population of circulating monocytes able 
to express Tie2 receptor (TEM) and showing tumor-
promoting properties [34]. In the CD14+ population, we 
found a variable expression of Tie2+ monocytes ranging 
from 3% to 62.8%, but in all patients analyzed we detected 
an increased expression after treatment with ibrutinib 
(Figure 6B, n=5, *P<0.05). Next, we cultured PBMCs 
from ibrutinib-treated patients to evaluate the capacity 
to generate NLCs. As shown in Figure 6C, ibrutinib did 
not prevent NLCs formation in vitro. In addition, NLCs 
viability as well as the capacity to support CLL cell 
survival were preserved (data not shown). Altogether, 
these results suggest that treatment with ibrutinib is able 
to induce modifications of the CD14+ population in CLL 
patients that may be evaluated in the complexity of the in 
vivo situation.
DISCUSSION
Ibrutinib is a first-in-class potent inhibitor of BTK 
that binds covalently to Cys-481 in the ATP-binding 
domain of the kinase. Inhibition of BTK in CLL cells 
determines a disruption of important signaling pathways 
involved in survival, migration and adhesion of leukemic 
cells [19, 35]. This peculiar effect leads to a substantial 
delocalization of CLL cells from the protective tissue 
compartment to the periphery interfering with pathogenetic 
mechanisms of recirculation and homing. One question 
that needs to be answered is whether ibrutinib may affect 
the non-malignant cellular compartment by modifying the 
nurturing and protective niches of CLL cells into tissue 
microenvironments. Recent studies have demonstrated 
off-target effects of ibrutinib that could actively contribute 
to modulate the CLL microenvironment [22, 23, 26, 36]. 
Ibrutinib mainly targets ITK in T cells influencing Th1/
Figure 4: Ibrutinib supports M2 signaling pathways by interfering with M1 polarization. NLCs were treated for 1 hour with 
ibrutinib 1 µM and then stimulated with LPS (100 ng/ml) or IL-4 (10 ng/ml) for 3 hours or 30 minutes respectively. Lysates were probed 
for pSTAT1, tSTAT1 A. pERK, tERK, pIĸB, tIĸB, pAKT, tAKT and actin B. following LPS stimulation investigating M1 polarization. 
C. PSTAT6, tSTAT6 and actin were determined after IL-4 stimulation for M2 polarization. D. NLCs were treated with ibrutinib and SHIP1 
induction was monitored by western blot and by immunofluorescence. Bar diagram depicts densitometric quantification of bands relative 
to pSTAT1, pSTAT6 and SHIP1, either in presence or absence of the corresponding stimulus, normalized on β-actin. Data are presented as 
mean ± SEM of 5 different NLCs samples (*P<0.05).
Oncotarget7www.impactjournals.com/oncotarget
Th2 polarization towards Th1 potentially modifying T 
cell anergy in CLL patients [23]. Moreover, impairment 
of NK function with decreased ADCC [22] and disruption 
of phagocytosis of rituximab-coated CLL cells by 
macrophages were related to ibrutinib treatment [26].
The ability of ibrutinib to effectively disrupt the 
crosstalk between CLL cells and NLCs is still unclear 
[18, 27, 28]. Our study provides new insights into the 
biological effects of ibrutinib treatment, reporting for the 
first time an extensive description of the molecular and 
functional modifications induced by ibrutinib treatment 
in NLCs. We demonstrate that ibrutinib is unable to 
completely antagonize the protective and nurturing role of 
NLCs allowing the protection of CLL cells from ibrutinib. 
This conclusion is in line with a recent report indicating 
that treatment with ibrutinib is not able to mobilize 
NLCs from niches into the blood and also to interfere 
with the pro-survival effects of NLCs [27]. Moreover, 
NLCs obtained in vitro from ibrutinib-treated patients are 
able to protect CLL cells as well as that of NLCs from 
untreated patients [27]. Here, we add a new explanation 
of this unwanted effect on NLCs. Ibrutinib targets BTK 
in NLCs affecting the activation by Src kinase-induced 
phosphorylation at Tyr551, autophosphorylation at Tyr223 
[37] and the activation of downstream-related pathways. 
The relevance of BTK expression in macrophages is 
related to regulation of macrophage lineage commitment. 
In accordance, BTK is involved in the induction of signals 
driving M1 polarization, but it also functions as a negative 
regulator of M2-polarizing signaling pathways [25]. 
The BTK inhibition mediated by ibrutinib potentiates 
the M2-skewed features typical of NLCs. Specifically, 
ibrutinib induces (i) inhibition of phagocytosis in line with 
downregulation of MAC1 expression, (ii) up-regulation of 
CD163 and CD206 known to be M2 macrophage markers 
and (iii) modulation of a peculiar cluster of genes involved 
in immune suppression. Of interest, in the M2 signature, 
ibrutinib promotes the expression of NAMPT able to 
Figure 5: IL-10 mediates pro-survival signals in CLL cells during treatment with ibrutinib. A. Viability of CLL cells 
were investigated treating both CLL cells and NLCs with ibrutinib 1 µM. CLL were harvested and divided into two fractions, one was 
placed back onto the autologous NLCs and the second was placed into wells without NLCs. Bar diagrams represent the mean relative CLL 
cell viabilities after 24, 48, 72h (n=9, *P<0.05, **P<0.01). B. Box plots show the percentage of IL-10 secreting cells in CD14+ NLCs 
population treated or not with ibrutinib for 1 hour relative to five independent experiments. C. Bar diagrams show the relative viability 
of CD19+ CLL cells treated with ibrutinib for 1 hour and then stimulated for 48 hours with IL-10 compared to untreated control (n=7, 
*P<0.05, **P<0.01). D. Western blot represents the activation of pro-survival signals induced by IL-10 either in presence or not of ibrutinib 
in one representative CD19+ CLL sample. Blots display pSTAT3, tSTAT3, pERK 1/2, tERK and actin.
Oncotarget8www.impactjournals.com/oncotarget
Figure 6: Ibrutinib alters the circulating monocytes in CLL patients. A. Bar diagrams show cumulative analysis of CD206 
(up) and CD11b (down) MFI for 5 different CLL patients in pre-treatment and after treatment samples. On the right, histograms show MFI 
of CD206 (up) and CD11b (down) for 3 representative CLL samples calculated using the corresponding isotype in pre-treated and after 
treatment samples. The blue histogram represents the post-treatment condition and the red shows the pre-treatment condition. B. Contour 
plots show the percentage of CD14+ Tie2+ monocytes before and after treatment with ibrutinib. On the right, diagram represents the 
percentage of positive CD14+ cells stained for Tie2 either before or after treatment with ibrutinib (n=5). C. Phase contrast photomicrographs 
and May-Grunwald Giemsa staining document the morphology of NLCs before and after treatment with ibrutinib.
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enhance the immunosuppressive phenotype of NLCs as 
well as their ability to protect CLL from apoptosis creating 
a CLL supporting microenvironment [11].
BTK is recruited to the Toll like receptor-4, during 
LPS stimulation, promoting phosphorylation of NFĸB and 
STAT1 activation, further sustaining the rationale of an 
involvement of BTK in M1 polarization [25]. When NLCs 
were exposed to LPS stimulation, STAT1 and its related 
signaling pathways were strongly activated. Treatment 
with ibrutinib, before LPS stimulation, diminished the 
activation of STAT1 arguing for a negative effect of 
this agent on M1 signaling pathway. On the contrary, 
the inhibition of BTK activity, promoted by ibrutinib, 
increased the induction of STAT6 also in presence of IL-4 
as mediator of M2 polarization. Again, ibrutinib induced 
the expression of another M2 modulator, SHIP1, which 
is an anti-inflammatory protein that turns-off PI3K-
dependent signaling [38].
CLL is partially rescued by ibrutinib-induced death 
by NLCs contact. We pointed our attention on IL-10, as a 
survival factor that may be involved in this effect given (i) 
ibrutinib intensely induces gene expression and secretion 
of IL-10 in NLCs, (ii) CLL cells express IL-10 receptor 
as previously demonstrated [39], (iii) elevated serum IL-
10 levels are associated with worse CLL patients survival 
[40]. The role of IL-10 in mediating CLL survival is still 
controversial, implying a possible involvement in CLL cell 
maintenance or in cell death. In particular, IL-10 provokes 
apoptosis decreasing Bcl-2 protein levels [41] or activating 
STAT1 protein in CLL cells [42]. On the contrary, IL-10 
enhances the survival of CLL cells acting as an autocrine 
growth factor [43, 44] and it is able to reduce cell death 
caused by hydrocortisone [39]. Here, IL-10 mediates 
pro-survival signals in CLL cells through the activation 
of STAT3, that is known to provide a survival advantage 
activating transcription of anti-apoptotic genes and ERK 
1/2 signaling pathway [45]. Treatment with ibrutinib is 
not able to totally counteract the pro-survival effect of IL-
10 in CLL cells arguing for its possible involvement in 
mediating resistance to ibrutinib.
Several studies demonstrate the considerable clinical 
success of ibrutinib showing a good safety profile and a 
promising clinical efficacy [14, 15]. Despite these exciting 
results, it had been immediately clear the limited capacity 
of this agent to induce a complete eradication of neoplastic 
clone, even if an improvement in quality of responses is 
seen when patients are treated for an extended period 
[46]. Persistent disease in blood and inside tissues can 
be detected in patients also after years of single-agent 
therapy. Moreover, some patients relapse during treatment 
and some patients fail to respond, sometimes developing a 
significant resistance to the treatment. Ibrutinib resistance 
is known in part to be related to acquired mutation in 
BTK at its binding site with a cysteine to serine mutation 
and others involving phospholipase Cγ2 (PLCγ2), an 
important downstream effector of BTK [47]. Nevertheless, 
the contribution of microenvironmental elements in CLL 
protection to ibrutinib may be envisioned and warrants 
further investigations in treated patients inside clinical 
trials. Our analysis of blood samples collected from 5 
patients before and after one month of treatment with 
ibrutinib, illustrates modifications of the monocytic 
population in the peripheral blood. In ibrutinib-treated 
samples, we detected an increased expression of M2 
markers as CD206 and CD11b and higher percentage of 
a small subpopulation of circulating monocytes able to 
express Tie2 receptor (TEM). The increased number of 
Tie2 expressing monocytes is somehow a dismal result, 
due to the peculiar pro-angiogenic activity and the tumor-
promoting M2 phenotype of this monocytic subset.
Overall, our results are in line with the reported 
observation by Boissard and colleagues that NLCs may 
mediate ibrutinib resistance in vitro, but further provide 
a mechanistic explanation for these undesired effects 
[27]. On the other hand, a very recent analysis of CLL-
associated macrophages in bone marrow biopsies obtained 
from CLL patients during ibrutinib treatment suggests 
that ibrutinib may disrupt CLL-macrophage interactions 
on the basis of a significant decrease in CD68+ cellular 
extension and a reduction of CXCL13 secretion [28]. It 
has to be considered that direct contact with CLL cells 
is essential for the supporting functions of NLCs. As 
consequence, a possible explanation of the apparent 
contradictory results may be that ibrutinib treatment in 
patients reduces the CLL infiltration inside bone marrow, 
probably interfering with the extent of CLL-NLCs contact 
and perhaps compensating for direct immunosuppressive 
effect of ibrutinib on NLCs. However, further evaluations 
of markers related to M1/M2 polarization in macrophages 
in bone marrow biopsies during ibrutinib treatment would 
be of interest. Ibrutinib is remarkably effective in CLL, but 
its mechanism of action inside the complexity of tumor 
microenvironment is not fully elucidated. For this reason, 
our results push for a more deep and accurate analysis of 
the immunomodulatory effects of ibrutinib to optimize its 
use and develop effective combination strategies. It could 
be of interest the observation that lenalidomide counteracts 
the pro-leukemia role and the immunodeficiency typical 
of NLCs inducing properties of pro-inflammatory cells 
[48]. The opposite effect exerted by lenalidomide and 
ibrutinib on NLCs is intriguing, suggesting future studies 
to understand whether lenalidomide may overcome the 
immunosuppressive effect on NLCs mediated by ibrutinib.
In conclusion, we proposed a new mechanism 
of action of ibrutinib that further miseducates NLCs, 
suggesting that this drug not only has an effect on the 
CLL clone but also extensively influences the cellular 
components of the CLL microenvironment. Ibrutinib 
supports the nurturing and protective behavior of NLCs 
potentiating their immunosuppressive profile and leading 
to secretion of unwanted survival factors. Our findings 
leave open the issue of how ibrutinib effects on CLL cells 
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may be optimized by associating it with other agents in 
order to combine its peculiar mechanism of action related 
to disruption of survival signaling pathways, migration 
and adhesion, with an effective disruption of protective 
milieu in tissue microenvironment.
MATERIALS AND METHODS
Patients and samples
Blood samples from untreated patients that matched 
standard diagnostic criteria for CLL were obtained 
from the Hematology Unit of Modena Hospital, Italy 
with a protocol approved by the Institutional Review 
Board. All patients provided written informed consent in 
accordance with the declaration of Helsinki. Peripheral 
blood mononuclear cells (PBMCs) were isolated by 
Ficoll density gradient centrifugation and used fresh or 
cryopreserved in RPMI-1640 medium (Life Technologies, 
Carlsbad, CA, USA), 50% fetal bovine serum (FBS), and 
10% dimethyl sulfoxide (DMSO) and stored in liquid 
nitrogen until use. To enrich for CLL cells, PBMCs were 
incubated with CD19 Microbeads (Miltenyi Biotec, 
Germany) obtain a purity > 99%, as assessed by flow 
cytometry. Ibrutinib was purchased from Selleckchem 
and was dissolved in DMSO, which was used as a vehicle 
control in all experiments. Ibrutinib was used at a dose of 
1 µM as in previous studies [18, 20, 23].
Nurse-like cells generation and analyses
PBMCs from CLL patients were suspended in 
RPMI with 10% FBS to a final concentration of 107/
ml, as previously published [5]. After 14 days, the non-
adherent CLL cells were harvested vigorously pipetting 
the contents of the well leaving untouched the adherent 
cells. NLCs typical morphology and immunophenotype 
were confirmed by microscopy and flow cytometry, 
respectively.
Cell treatments and viability
For co-culture with NLCs, PBMCs were suspended 
in medium to a concentration of 107/ml and incubated for 
at least 10 days. To assess the impact of ibrutinib on CLL 
cell viability, both CLL and NLCs were concomitantly 
exposed to ibrutinib. In detail, CLL cells were removed 
by thoroughly pipetting and divided into 2 fractions. 
One was placed back onto the autologous NLCs and 
the second fraction was placed into wells without NLCs 
either. After 30 minutes, ibrutinib or DMSO was added 
in the corresponding wells. For all these experiments, 
ibrutinib was used at a dose of 1 µM. CLL cell viability 
was determined collecting non-adherent cells in the 
corresponding well and analyzed by flow cytometry using 
annexin V-FITC and propidium (PI) staining (eBioscience, 
San Diego, CA, USA) after 24h, 48h and 72h. For IL-
10 stimulation, CD19+ CLL cells were pre-incubated in 
complete RPMI with or without ibrutinib for 1h at 37 °C 
and then stimulated by the addition of 0.1-100 ng/ml IL-10 
(PeproTech, Rocky Hill, NJ, USA). For viability assays, 
we calculated the mean relative viabilities to account for 
variability in spontaneous apoptosis rates in different 
patients’ samples. We define the mean relative viability as 
the mean CLL cell viability of a particular sample (treated 
with ibrutinib in the presence or absence of NLCs at a 
certain time point), divided by the mean cell viability of 
the same sample at the same time point of control CLL 
cells cultured in suspension culture [49].
FITC-DEXTRAN uptake and confocal 
microscopy of NLCs
For confocal microscopy experiments with NLCs, 
PBMCs from CLL patients were plated on glass coverslips 
in 24-wells plate in complete medium to generate NLCs 
as indicated. After 10 days, NLCs were treated with 
ibrutinib for 30 minutes and 1 hour, then the coverslips 
were transferred in new wells and incubated for 15 
minutes at 37 °C in PBS 5% FCS with 1 mg/ml of FITC-
DEXTRAN (Sigma). Then, coverslips were fixed (4% 
paraformaldehyde for 10 minutes at RT), permeabilized 
(0.1% saponin for 20 minutes at RT), blocked with goat 
serum (30 min at 4 °C) and incubated with anti-phalloidin-
Alexa 568 (Invitrogen Life Technologies, 1:100, 1 hour at 
4 °C) followed by secondary antibody Goat anti-Rabbit-
Alexa 594 (Invitrogen Life Technologies, 1:300, 1 hour at 4 
°C). Samples were counter-stained with DAPI and mounted 
in SlowFade Gold reagent (both from Invitrogen). Slides 
were analyzed using a TCS SP5 laser scanning confocal 
microscope equipped with 4 lasers (Leica Microsystems, 
Milan, Italy), images acquired with the LAS AF software 
and processed with Adobe Photoshop (Adobe Systems, San 
Jose, CA). Pixel intensity analyses were performed using 
the ImageJ (downloadable at http://rsbweb.nih.gov/ij/) and 
the LAS Application Suite (Leica Microsystems) softwares. 
Mean pixel intensity was calculated by defining a region 
of interest (ROI) and measuring green fluorescence pixel 
intensity. Results are expressed as fold change compared to 
untreated control [11].
MTT assay and viability
NLCs activation was monitored using a yellow 
tetrazolium MTT assay (Trevigen, Gaithersburg, 
MD, USA). In this assay, dehydrogenases expressed 
by metabolically active cells convert MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-dyphenyltetrazolium 
bromide) into intracellular purple formazan. NLC cells 
were cultured into a 96-well plate for 12 days and then 
treated with ibrutinib for 24 hours. Cells were then 
incubated with MTT at 37 °C for 24 hours, followed by a 
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4h-incubation with 100 µL detergent reagent. Absorbance 
readings were performed at 570 nm in a microplate reader 
(Infinite M200, Tecan, Männedorf, Switzerland).
NLCs viability were tested by Annexin V-PI staining 
and analyzed by flow cytometry.
Flow cytometry
To determine the abundance of NLCs surface 
markers, after 10 days the floating cells were removed 
by washes and the adherent cells were treated with 
ibrutinib for 1 hour or 24 hours, then detaching NLCs 
with PBS/EDTA solution. Cells were stained with the 
following antibodies and corresponding isotype controls: 
APC-conjugated CD14, CD163 (both BD Biosciences 
Pharmingen, San Jose, CA, USA), PE-conjugated CD11b 
CBRM 1/5 (the activated epitope of CD11b MAC-1) 
(eBioscience), pBTK Tyr551 (GeneTex, USA), pBTK 
Tyr223 (Novus Biological, Littleton CO, USA). Events 
were acquired using a FACSCalibur (Becton Dickinson, 
San José, CA, USA) or FACSAria cytometers and then 
analyzed by FlowJo Software (Tree Star, Ashland, OR, 
USA). In all the experiments, an isotype control sample for 
each condition was acquired to exclude autofluorescence 
background.
Real time PCR
RNA was extracted with the RNeasy Plus Mini 
kit (Qiagen, Valencia, CA, USA). RNA (100ng) 
was reverse transcribed using Transcription High 
fidelity cDNA Synthesis kit (Roche Applied Science, 
Penzeberg, Germany). All samples were analyzed in 
real time on LightCycler 480v.2 (Roche) in duplicate. 
Amplification of the sequence of interest was normalized 
to an housekeeping reference gene (Glyceraldehyde 
3-phosphate dehydrogenase, GAPDH) and compared to 
a calibrator sample (Universal Human Reference RNA; 
Stratagene, Cedar Creek, TX). Primers are listed in 
Supplementary Table S1.
Immunoblotting
Proteins (80 µg/lane) were electrophoresed on 
SDS-polyacrylamide gradientgels (Biorad laboratories, 
Hercules, CA, USA). Membranes were immunoblotted 
with primary antibodies listed in Supplementary 
Table S2 and incubated with species-specific horseradish 
peroxidase (HRP)-conjugated secondary antibody (diluted 
1:50000; GE Healthcare, Uppsala, Sweden) for 1 hour 
and developed using HRP conjugates WesternBright 
Sirius (Advasta, Menlo Park, CA, USA). Images were 
acquired and analyzed using Image Lab Software (Biorad 
Laboratories). After 10 days of culture, CLL cells were 
carefully removed by thoroughly pipetting, then NLCs 
were pretreated with ibrutinib for 1h following to 
stimulation with 100 ng/ml of LPS (Sigma-Aldrich) for 
3 hours, 10 ng/ml of IL4 (Peprotech) for 30 minutes. 
CLL cells were stimulated with 1 ng/ml IL-10 after a pre-
treatment of 1h with ibrutinib.
Cytokine secretion assay (CSA)
To determine IL-10 secretion, NLCs were 
cultured for 10 days and then treated with ibrutinib for 
24 hours and analyzed using CSA for IL-10 according 
to manufacturer’s instructions (CSA Detection kit; 
Miltenyi Biotec). NLCs were immunostained with IL-
10 catch reagent and incubated for 2 hours at 37 °C 
to allow cytokine secretion. After washes, cells were 
labeled with IL-10 Detection antibody conjugated to PE 
and CD14 APC Ab. An isotype control sample for each 
condition was acquired to exclude autofluorescence 
background.
Ex vivo flow cytometry analysis
Peripheral blood samples from CLL patients treated 
with ibrutinib were collected pre-treatment and after one 
month of treatment. PBMCs were stained with APC- 
conjugated CD14, CD206, CD11b (BD Biosciences) 
and Tie2 (R&D System). Events were acquired using 
a FACSAria cytometer and then analyzed by FlowJo 
Software.
Statistical analysis
Data were analyzed using SPSS version 20.0 (SPSS, 
Chicago, IL, USA). In some experiments, results were 
normalized on control (100%) (vehicle-treated samples). 
Normalization was performed by dividing the value of 
a particular sample treated with ibrutinib to the value of 
the corresponding sample treated with vehicle DMSO. 
P values were calculated by Student t test (*P<0.05, 
**P<0.01). Data are presented as mean and standard error 
of the mean (SEM) is depicted as error bars.
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